The year 2026 is shaping up to be a pivotal moment in healthcare, with a wave of pharmaceutical advancements poised to address some of the world’s most challenging diseases. From potential breakthroughs in Alzheimer’s and ALS treatment to innovative approaches to cholesterol management and bone regeneration, a host of new therapies are nearing availability.This article details several key developments expected to gain traction next year, offering new hope for patients and reshaping the landscape of modern medicine, particularly with a growing emphasis on oral medications and preventative care.
Breakthroughs once considered science fiction are rapidly becoming reality in the medical field. Over the next year, several pharmaceutical advancements are expected to launch or gain traction, promising to significantly improve – and in some cases, transform – the lives of patients battling conditions with limited treatment options, such as Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and Huntington’s disease. These include life-saving therapies like new ‘in vivo’ CAR-T cell therapies for cancer, as well as treatments designed to extend years of healthy living, such as new medications that drastically lower LDL or “bad” cholesterol, and therapies to promote bone regeneration beyond simply slowing osteoporosis. 2026 is poised to be a year of significant progress in healthcare.
Oral Weight Loss Medications on the Horizon
Table of Contents
- Oral Weight Loss Medications on the Horizon
- Lowering Cholesterol Without Injections
- Slowing the Progression of Alzheimer’s and Multiple Sclerosis
- Hope for Huntington’s Disease and ALS
- Regenerating Lost Bone
- Relief from Hot Flashes Without Breast Cancer Concerns
- Managing Asthma Without Bronchodilators
- A Vaccine Against Group B Strep
- New Hair Growth and No More Gray!
- Medications to Extend Lifespan
The market for obesity and diabetes medications is on the cusp of a significant shift. The development of medications like Ozempic, Wegovy, and Mounjaro marked an initial breakthrough, effectively managing blood glucose while also promoting substantial weight loss, even in individuals with a history of dieting. However, these treatments require injections, which can be a barrier for those with a fear of needles.
For decades, researchers have sought an oral alternative to insulin injections for people with diabetes. Now, that goal is within reach with the development of new weight loss drugs. These oral medications are expected to become available in Europe in 2026 as they move through the regulatory process with the European Medicines Agency (EMA). Leading pharmaceutical companies, including Novo Nordisk, Lilly, AstraZeneca, and Roche, are driving this progress in the fields of type 2 diabetes and obesity.
The pill mimics the action of the GLP1 hormone, with similar potential side effects like nausea and constipation, but offers the convenience of avoiding injections. This is a significant advantage for many patients, and the medication can be stored at room temperature and taken at any time of day, even on an empty stomach.
Lowering Cholesterol Without Injections
Laroporvstat and MK-0616 are the first two oral medications designed to directly inhibit the PCSK9 protein, which elevates levels of “bad” cholesterol in the blood. Their ease of use – a single daily pill – is expected to improve patient adherence compared to current injectable treatments. Studies have shown these medications can reduce LDL cholesterol levels by up to 50%. This is particularly important given that hypercholesterolemia affects 50% of the population, half of whom are unaware of their condition and do not receive treatment, leading to plaque buildup in arteries and increasing the risk of cardiovascular disease, heart attack, and stroke.
AstraZeneca and Merck are collaborating on this advancement, with research in advanced stages and preparations underway to submit applications for regulatory approval from the FDA and EMA.
Slowing the Progression of Alzheimer’s and Multiple Sclerosis
Unlike existing Alzheimer’s treatments that primarily address symptoms, a new drug under development by Lilly represents a shift towards therapies that actually slow the disease’s progression. Studies have also shown that in 75% of patients, the drug removes amyloid plaques, which are believed to contribute to neuronal death. This injectable medication is administered monthly for 18 months, and improvements have been observed to persist for up to three years after treatment completion. Kisunla – its designated name – is expected to change how this neurodegenerative disease is diagnosed and treated. It will be available in Spain in 2026, and in Europe and other markets between 2026 and 2027.
Roche is also developing an oral medication, fenebrutinib, currently in phase 3 trials, to slow the progression of multiple sclerosis by targeting both acute and chronic inflammation.
Hope for Huntington’s Disease and ALS
Pridopidine, an oral medication, is a potent and selective drug designed to stimulate key neuroprotective mechanisms in both Huntington’s disease and ALS. It is currently in phase 3 trials (the final stage before seeking regulatory approval) and has shown promising results in ALS patients, as published in the journal Nature Medicine. In the case of ALS, advanced clinical development is underway, with a phase 3 trial planned for January 2026.
Developed by Ferrer, this medication is the first treatment aimed at slowing the progression of Huntington’s disease, a condition currently managed with therapies that only alleviate symptoms and provide palliative care. This could represent a major advancement in the treatment of ALS as well.
Regenerating Lost Bone
Entera Bio is developing the first pill shown to significantly increase bone mineral density in individuals with osteoporosis or low bone mineral density in the femoral neck, hip, and lumbar spine, with a rapid effect. Studies have also demonstrated strengthening of both the outer layer and internal structure of the bone.
An oral treatment rapidly increases bone mineral density in cases of osteoporosis
The effect is comparable to current injectable medications, but the oral form could improve treatment adherence. The drug is currently in late-stage research and awaiting the start of the regulatory approval process.
Relief from Hot Flashes Without Breast Cancer Concerns
The first non-hormonal medication for hot flashes safe for patients with breast cancer is on the horizon. Lynkuet is the first non-hormonal treatment for hot flashes and sleep disturbances during menopause, and it may be suitable for women undergoing hormone therapy for breast cancer. These patients, as well as those with a history of breast cancer, are typically unable to use hormone replacement therapy to manage hot flashes and sleep disturbances due to an increased risk of recurrence or new tumor development.
Unlike other similar drugs, this development from Bayer has, for the first time, demonstrated potential use in breast cancer patients receiving hormone therapy, also showing significant improvements in symptoms and mood (New England Journal of Medicine). Furthermore, this medication blocks two neurokinins (1 and 3), with the latter preventing the severe liver damage that can be caused by other non-hormonal treatments.
Linkuet recently received approval from the EMA for marketing in Europe and is already authorized in the United Kingdom and Canada. Approval from the U.S. Food and Drug Administration is still pending.
Managing Asthma Without Bronchodilators
The goal of freeing patients with severe asthma from reliance on bronchodilators is becoming increasingly attainable. Depemokimab is the first ultra-long-acting biologic injectable for type 2 (severe) asthma, with a dose administered every six months in adults and adolescents over 12 years of age. Studies have also shown that extending the interval between doses does not affect the outcome and improves treatment adherence. The market launch of this development from GSK is imminent following its recent approval by the European Medicines Agency (EMA).
Asthma affects 2.5 million people in Spain (10% of adults and 15% of adolescents). Patients with type 2 asthma are typically treated with inhaled corticosteroids to reduce airway inflammation, and a long-acting bronchodilator is often added in persistent cases. This biologic is expected to improve their quality of life and reduce their dependence on these frequently administered medications.
A Vaccine Against Group B Strep
Administered to pregnant women, this vaccine developed by Pfizer against the six most common serotypes of Group B Streptococcus is designed to prevent infants from contracting serious and potentially life-threatening infections such as meningitis, sepsis, or pneumonia. This is the first vaccine against this bacteria, which is commonly carried by healthy individuals without causing problems, but can be transmitted to the baby during childbirth and cause illness. It would also eliminate the need for routine microbiological screening during pregnancy and antibiotic administration during labor, two preventative measures that are difficult to implement in developing countries. The vaccine is in its final phase of study (phase 3) and will then begin the regulatory process.
New Hair Growth and No More Gray!
In a very early stage of development, this treatment from Absci has already shown promising results against androgenetic alopecia, the most common form of hair loss (affecting 80% of men and 35% of women) due to a combination of genetic and hormonal factors.
ABS-201 is a monoclonal antibody designed by artificial intelligence that affects a receptor involved in the hair cycle: prolactin, which had never before been considered for treating baldness.
During the hair life cycle, hair follicles enter a latent phase, and normally, a new hair grows when the old one falls out. In people with alopecia, the hair remains latent and does not “sprout,” something that ABS-201 achieves. It doesn’t just stop hair loss; it encourages new hair growth.
ABS-201 is the result of artificial intelligence. It doesn’t just stop hair loss; it sprouts new hair
ABS-201 is the result of numerous computer simulations that optimized the antibody’s potency, reduced the risk of adverse reactions, and shortened the development time. Testing in primates not only restored full hair growth but also unexpectedly resulted in the new hair growing in without gray hairs. A first human trial began in Australia this December. It won’t be available in 2026, but it offers new hope for hair loss treatment.
Medications to Extend Lifespan
While aging is not recognized as a disease, life expectancy is increasing, and medicine aims to extend years of healthy life. In this context, some medications authorized for use in different diseases have been identified as having a geroprotective effect on those taking them.
These drugs are substances that combat aging and associated diseases, delaying or reversing biological processes, although there are currently no drugs with this specific indication approved for humans.
Examples of drugs with geroprotective effects and their mechanisms of action include metformin, rapamycin, resveratrol, glycine + N-acetylcysteine, and nicotinamide mononucleotide, but their use is not approved for longevity medicine.
